何雪陽,張晉寧,蔡永輝,黃佳欣
·論著·
煙霧病合并動(dòng)脈瘤栓塞治療6例及文獻(xiàn)復(fù)習(xí)
何雪陽,張晉寧,蔡永輝,黃佳欣
目的 探討煙霧病(MMD)合并顱內(nèi)動(dòng)脈瘤的血管內(nèi)介入治療的特點(diǎn)及經(jīng)驗(yàn)。方法 回顧性分析2007年5月~2015年6月期間6例煙霧病合并動(dòng)脈瘤栓塞患者的臨床資料及影像學(xué)表現(xiàn)。以腦實(shí)質(zhì)內(nèi)出血發(fā)病的3例患者中,2例患者考慮為合并非責(zé)任動(dòng)脈瘤,行單純栓塞;1例患者考慮為假性動(dòng)脈瘤,為出血責(zé)任病灶,應(yīng)用20%Glubran閉塞動(dòng)脈瘤并載瘤動(dòng)脈。1例未出血的眼動(dòng)脈瘤患者行支架輔助彈簧圈栓塞治療。2例表現(xiàn)蛛網(wǎng)膜下腔出血的患者,急診行CTA檢查示顱底動(dòng)脈環(huán)附近動(dòng)脈瘤,行單純栓塞治療。結(jié)果 6例患者手術(shù)均取得成功,5例彈簧圈栓塞患者中,1例取得致密栓塞,隨訪結(jié)果良好。結(jié)論 對于煙霧病合并動(dòng)脈瘤患者,因煙霧病有容易發(fā)生缺血并發(fā)癥的風(fēng)險(xiǎn),選擇血管內(nèi)栓塞治療的效果是確切的,相對于開顱動(dòng)脈瘤夾閉術(shù)是安全的。
動(dòng)脈瘤;煙霧??;血管內(nèi)治療
煙霧病是一種病因尚未明確,主要表現(xiàn)為雙側(cè)頸內(nèi)動(dòng)脈及顱底動(dòng)脈環(huán)緩慢而又逐漸進(jìn)展的狹窄、閉塞,同時(shí)伴有顱底煙霧狀血管增生的疾病。煙霧病的臨床癥狀通常表現(xiàn)為腦缺血和出血,其中,煙霧病合并的動(dòng)脈瘤是其顱內(nèi)出血的主要原因。煙霧病合并動(dòng)脈瘤的發(fā)生率大約在3.4%~14.8%之間,遠(yuǎn)遠(yuǎn)高于正常人群的動(dòng)脈瘤發(fā)生率。合并動(dòng)脈瘤的部位各家報(bào)道不同,其中較為常見的是合并基底動(dòng)脈尖動(dòng)脈瘤[1]。對于煙霧病合并動(dòng)脈瘤的治療,目前較為一致的意見是血管內(nèi)途徑介入栓塞要明顯優(yōu)于開顱動(dòng)脈瘤夾閉術(shù)。福建醫(yī)科大學(xué)附屬泉州第一醫(yī)院神經(jīng)外科自2007年5月~2015年6月開展腦血管病介入治療以來,共收治煙霧病合并動(dòng)脈瘤患者6例,均采用血管內(nèi)介入治療,取得比較滿意的效果?,F(xiàn)總結(jié)分析如下。
1.1 一般資料 本組患者中,男2例,女4例;年齡42~56歲,平均年齡47.3歲。本組患者中有3例患者因自發(fā)性腦出血直接行DSA檢查,其中第1例患者為腦室內(nèi)出血,檢查發(fā)現(xiàn)煙霧病合并后交通動(dòng)脈瘤;第2例患者為煙霧病合并基底動(dòng)脈瘤,均考慮為非本次出血性因素,給予單純栓塞;第3例患者檢查發(fā)現(xiàn)煙霧病血管假性動(dòng)脈瘤,考慮為出血責(zé)任病灶,應(yīng)用20%Glubran給予動(dòng)脈瘤并載瘤動(dòng)脈閉塞。1例未出血,因頭暈等癥狀行CTA檢查發(fā)現(xiàn)煙霧病和左側(cè)眼動(dòng)脈瘤,于DSA檢查確診后行支架輔助彈簧圈栓塞治療。2例表現(xiàn)為蛛網(wǎng)膜下腔出血患者,急診行DSA檢查發(fā)現(xiàn)脈絡(luò)膜前動(dòng)脈動(dòng)脈瘤(圖1)及基底動(dòng)脈尖動(dòng)脈瘤(圖2),行單純栓塞治療。
1.2 方法 手術(shù)均采用全身麻醉,股動(dòng)脈穿刺置入6F動(dòng)脈鞘后即全身肝素化。根據(jù)患者血管迂曲情況,選擇6F Chaperon或長鞘加Neuron導(dǎo)引導(dǎo)管,導(dǎo)引導(dǎo)管通常放置于顱底(前循環(huán)動(dòng)脈瘤)或椎動(dòng)脈C2拐彎處(后循環(huán)動(dòng)脈瘤),微導(dǎo)管通常選擇常用的Echelon 10或Headway 17,閉塞血管時(shí)則選用Marathon,彈簧圈一般選擇電解脫或機(jī)械解脫的彈簧圈。第2例患者造影后評估需要支架輔助栓塞,術(shù)中按患者體重臨時(shí)予鹽酸替羅非班(欣維寧)12 ml靜脈注射,并按每小時(shí)4 ml的速度微泵注入維持至第2 d,改予阿斯匹林100 mg及氯吡格雷75 mg口服。第6例患者以基底節(jié)區(qū)、腦室出血發(fā)病,DSA檢查發(fā)現(xiàn)煙霧病血管假性動(dòng)脈瘤,選擇動(dòng)脈瘤連同載瘤動(dòng)脈一起閉塞,于Marathon微導(dǎo)管到位后注入少量20%Glubran,將動(dòng)脈瘤連同載瘤動(dòng)脈成功閉塞。術(shù)后均常規(guī)應(yīng)用尼莫地平預(yù)防腦血管痙攣,為防止低灌注,同時(shí)維持收縮壓在130 mmHg左右。
本組6例患者手術(shù)均取得成功。5例彈簧圈栓塞患者中,1例患者取得致密栓塞,按Rammond分級為Ⅰ級;4例患者為瘤頸殘余,按Rammond分級為Ⅱ級,術(shù)后均未出現(xiàn)新增并發(fā)癥。這4例患者于術(shù)后6個(gè)月腦血管造影復(fù)查示,動(dòng)脈瘤均處于穩(wěn)定狀態(tài),無彈簧圈壓縮;3例瘤頸殘余患者中2例患者的殘余進(jìn)一步縮小,動(dòng)脈瘤進(jìn)一步愈合;1例患者穩(wěn)定,瘤頸仍有顯影,同術(shù)后即刻相比無變化。另1例Glubran栓塞患者血管造影顯示,原有閉塞血管未再通,未見其他部位動(dòng)脈瘤。
A:栓塞前; B:栓塞后,有瘤頸殘余圖1 脈絡(luò)膜前動(dòng)脈動(dòng)脈瘤患者栓塞前、后腦血管造影檢查
A、B:栓塞前; C:栓塞后圖2 基底動(dòng)脈瘤患者栓塞前、后腦血管造影檢查
Maki和Nakata在1965年首先報(bào)道了煙霧病合并動(dòng)脈瘤[2]。煙霧病合并動(dòng)脈瘤的發(fā)生率大約10%左右,一般可分為3種類型,即發(fā)生于顱底大動(dòng)脈的動(dòng)脈瘤;發(fā)生于周圍腦動(dòng)脈的動(dòng)脈瘤,如脈絡(luò)膜前、后動(dòng)脈的動(dòng)脈瘤;發(fā)生于煙霧病血管的假性動(dòng)脈瘤[2]。其發(fā)生機(jī)制各有不同。發(fā)生顱底大動(dòng)脈環(huán)的動(dòng)脈瘤多與異常血流學(xué)模式有關(guān),而發(fā)生于煙霧病血管的假性動(dòng)脈瘤則多與煙霧病血管的異常結(jié)構(gòu)有關(guān)[3]。Kawaguchi等統(tǒng)計(jì)發(fā)現(xiàn),煙霧病合并的動(dòng)脈瘤中,分布于Willis環(huán)、基底節(jié)區(qū)、煙霧病血管之間的動(dòng)脈瘤的發(fā)生率比大約是3∶1∶1[4]。其中,動(dòng)脈瘤發(fā)生于后循環(huán)的又較為多見,這可能與前循環(huán)大動(dòng)脈閉塞后顱內(nèi)供血主要通過后循環(huán)向前代償,后循環(huán)負(fù)擔(dān)加重,血流增多,對血管壁的沖擊壓力增大有關(guān),為血液動(dòng)力學(xué)相關(guān)性動(dòng)脈瘤[4]。
發(fā)生于Willis環(huán)的動(dòng)脈瘤,由于血流的持續(xù)沖擊,常難以自愈,且容易持續(xù)增大,最后破裂出血,故需要積極地手術(shù)干預(yù)[1]。成人非出血性煙霧病患者中約有3.6%左右的患者合并有顱底大血管動(dòng)脈瘤,一半左右見于后循環(huán),且隨著患者年齡的增大,合并動(dòng)脈瘤的發(fā)生率越來越高[1],這也從另一方面表明顱底動(dòng)脈環(huán)動(dòng)脈瘤與血流的長期沖擊有關(guān)。一項(xiàng)包括42例出血性煙霧病患者的隨訪研究中發(fā)現(xiàn),患者的再出血率平均為7.09%,二次出血的恢復(fù)良好率從45.5%降至21.4%,病死率從6.8%升至28.6%[3]。因此,對于顱底大血管的煙霧病合并動(dòng)脈瘤,即便未破裂出血,也應(yīng)積極治療。對于發(fā)生在煙霧病血管中的假性動(dòng)脈瘤,因?yàn)闊熿F病患者本身即存在著較大的缺血性梗死風(fēng)險(xiǎn),若行開顱夾閉手術(shù),即便事先作了顱內(nèi)外血運(yùn)重建手術(shù),也不能降低梗死缺血的風(fēng)險(xiǎn)。所以,對于煙霧病血管中的假性動(dòng)脈瘤,是否行開顱手術(shù)目前尚存在爭論。并且,對于是否有必要介入治療目前也無明確意見,Kawaguchi等報(bào)道的病例表明假性動(dòng)脈瘤常常在保守治療后自行消失[4],而 Hamada等則報(bào)道類似病例在保守治療過程中再次發(fā)生出血[5]。折中的方法似乎是充分評價(jià)載瘤動(dòng)脈后再?zèng)Q定是否行血管內(nèi)治療,若載瘤動(dòng)脈易于到達(dá),治療風(fēng)險(xiǎn)不大,則建議治療。
對于煙霧病合并動(dòng)脈瘤的患者,由于以下的一些因素,行開顱夾閉手術(shù)的病死率、致殘率極高,目前已基本讓位于血管內(nèi)介入治療。首先,煙霧病患者往往有大量顱內(nèi)外吻合血管及顱內(nèi)增生血管,失去了正常的解剖結(jié)構(gòu),大大增加了手術(shù)的難度。開顱手術(shù)極易損傷這些血管,引起繼發(fā)缺血、梗死;其次,煙霧病患者往往處于潛在或明確的缺血狀態(tài)中,臨時(shí)阻斷夾的應(yīng)用很可能對于原本就處在缺血狀態(tài)的腦組織帶來不可逆的損傷[6];第三,手術(shù)中出血、全身麻醉等因素容易引起血壓下降,即便及時(shí)升壓治療,也容易引起繼發(fā)缺血;最后,開顱手術(shù)對手術(shù)入路的要求也極高,適應(yīng)證窄。其要求術(shù)前事先DSA檢查,明確術(shù)野中沒有明顯的側(cè)支循環(huán)血管建立,以免在術(shù)中受到損傷,引起相應(yīng)供血區(qū)域缺血。同時(shí)行動(dòng)脈瘤夾閉后局部載瘤動(dòng)脈變窄,加重了原先因?yàn)闊熿F病引起的血管狹窄的程度[7]。而血管內(nèi)治療由于其特殊路徑,除了共同的麻醉因素外,其余的因素則不復(fù)存在。但對于血管內(nèi)途徑無法栓塞的煙霧病合并動(dòng)脈瘤,需要行顱內(nèi)外血管搭橋并載瘤動(dòng)脈夾閉,或同時(shí)需要行顱內(nèi)外血管搭橋以改變?nèi)毖Y狀的患者,開顱手術(shù)也是不得已的選擇[8]。
在給煙霧病合并動(dòng)脈瘤的患者行血管內(nèi)治療的過程中,由于自發(fā)性蛛網(wǎng)膜下腔出血或其他部位腦出血后的繼發(fā)腦血管痙攣,使煙霧病患者原有的腦組織缺血將可能更加嚴(yán)重;故在栓塞手術(shù)過程中,容易并發(fā)缺血性事件。為此,在手術(shù)過程中應(yīng)注意保持血壓平穩(wěn),避免血壓下降幅度過大,以免引起腦灌注不足。其次,煙霧病患者的側(cè)支循環(huán)代償往往已達(dá)到極限,任何的血管阻塞均可能引起災(zāi)難性的后果[9-10],所以在顱底大血管動(dòng)脈瘤的栓塞治療過程中,應(yīng)高度強(qiáng)調(diào)保持載瘤動(dòng)脈的通暢。為避免彈簧圈脫入載瘤動(dòng)脈,對于寬頸動(dòng)脈瘤的栓塞,無論是支架還是球囊的應(yīng)用,都應(yīng)該充分考慮。但應(yīng)用支架或球囊等輔助手段,本身也帶來了缺血的風(fēng)險(xiǎn)[11-12]。Jeon等報(bào)道了2例煙霧病合并基底動(dòng)脈尖寬頸動(dòng)脈瘤,應(yīng)用“Y”形支架技術(shù),將支架放于雙側(cè)大腦后動(dòng)脈,1例患者在術(shù)中出現(xiàn)支架內(nèi)血栓,術(shù)后患者出現(xiàn)中腦缺血癥狀[13]。Arta等報(bào)道了5例采取血管內(nèi)治療的煙霧病合并基底尖動(dòng)脈瘤患者, 其中3例患者應(yīng)用了球囊輔助技術(shù)。1例患者在術(shù)中出現(xiàn)一過性瞳孔散大,1例患者在術(shù)后出現(xiàn)動(dòng)眼神經(jīng)麻痹,考慮均與術(shù)中缺血有關(guān)[14]。最后,在手術(shù)操作中,還應(yīng)考慮導(dǎo)引導(dǎo)管對動(dòng)脈血流的阻塞作用,以及局部刺激引起血管痙攣的可能。這些因素均可能引起遠(yuǎn)端腦組織缺血,故在導(dǎo)引導(dǎo)管到位后應(yīng)手推造影,排除是否繼發(fā)血管痙攣或血管腔被導(dǎo)管完全占據(jù)導(dǎo)致血流減慢。若血流明顯受阻,則手推造影導(dǎo)管前端可見造影劑殘留,此時(shí)應(yīng)后撤導(dǎo)引導(dǎo)管,并再次手推造影檢查,避免出現(xiàn)繼發(fā)性腦缺血。
[1] Yeon JY,Kim JS,Hong SC.Incidental major artery aneurysms in patients with non-hemorrhagic moyamoya disease[J].Acta Neurochir(Wien),2011,153:1263.
[2] Maki Y,Nakata Y.An autopsy case of hemangiomatous malformation of bilateral internal carotid arteries at the base of the brain[J].No To Shinkei,1965,17:764.
[3] Mark RH,John PD.Handbook of cerebrovascular disease and neurointerventional technique[J].Am J Neuroradiol,2009,30:571.
[4] Kawaguchi S,Sakaki T,Morimoto T.Characteristics of intracranial aneurysms associated with moyamoya disease,A review of 111 cases[J].Acta Neurochir (Wien),1996,138:1287.
[5] Hamada J,Hashimoto N,Tsukahara T.Moyamoya disease with repeated intraventricular hemorrhage due to aneurysm rupture:Report of two cases[J].J Neurosurg,1994,80:328.
[6] Hanakita J,Miyake H,Nagayasu S.Surgical treatment of cerebral aneurysm and cerebral artery ectasia with moyamoya vessels[J].Surg Cerebr Stroke,1988,16:175.
[7] Yu JL,Yuan YJ,Zhang D.Moyamoya disease associated with arteriovenous malformationand anterior communicating artery aneurysm:A case report and literature review[J] .Exp Therapeutic Med,2016,12:267.
[8] Zhang L,Kan X,Zhang YD.Treatment strategies for aneurysms associated with moyamoya disease[J].Int J Med Sci,2015,12:234.
[9] Hallemeier CL,Rich KM,Grubb RL Jr,etal.Clinical features and outcome in North American adults with moyamoya phenomenon[J].Stroke,2006,37:1490.
[10] Kuroda S,Ishikawa T,Houkin K,etal.Incidence and clinical features of disease progression in adult moyamoya disease[J].Stroke,2005,36:2148.
[11] Dalfino J,Nair AK,Drazin D,etal.Strategies and outcomes for coiling very small aneurysms[J].World Neurosurg,2014,81:765.
[12] Saliou G,Sacho RH,Power S,etal.Natural history and manage-ment of basilar trunk artery aneurysms[J].Stroke,2015,46:948.
[13] Jeon P,Kim BM,Kim DJ,etal.Y-configuration double-stent-assisted coiling using two closed-cell stents for wide-neck basilar tip aneurysms[J].Acta Neurochir (Wien),2014,156:1677.
[14] Arita K,Kurisu K,Ohba S,etal.Endovascular treatment of basilar tip aneurysms associated with moyamoya disease[J].Neuroradi-ology,2003,45:441.
(收稿2016-09-24 修回2016-11-13)
Endovascular treatment of intracranial aneurysms associated with moyamoya disease
HEXue-yang,ZHANGJin-ning,CAIYong-hui,etal.
DepartmentofNeurosurgery,QuanzhouNo.1Hospital,FujianMedicalUniversity,Quangzhou362000,China
Correspondingauthor:CAIYong-hui
Objectives To discuss the endovascular management strategies and experiences of the intracranial aneurysm associated with moyamoya disease(MMD). Methods The clinical and angiographic records of 6 patients diagnosed as the intracranial aneurysm associated with moyamoya disease were retrospectively reviewed.Of 3 patients presented with intracranial hematoma, incidental aneurysm was found in 2 patients.Each was treated with conventional embolization. One pseudoaneurysm was found to be blame for hematoma in the third patient and was occluded by internal trapping with 20%Glubran. The patient with asymptomatic ophthalmic aneurysm was treated with stent assisted coiling successfully. For 2 patients with SAH, ruptured aneurysm along the territory of Willis circle was shown by CTA and was embolized emergently. Results 6 patients surgical success.Of 5 patients with coilings, 1 reached complete obligation and maintained stable at follow-ups. Conclusions Considering the high risk for periprocedural ischemic events with moyamoya disease, endovascular treatment for intracranial aneurysm associated with moyamoya disease is efficacious, and might be a safer option compared with microneurosurgery.
intracranial aneurysm; Moyamoya disease; endovascular treatment
10.3969/j.issn.1672-7770.2017.01.014
362000 福建醫(yī)科大學(xué)附屬泉州第一醫(yī)院神經(jīng)外科
蔡永輝
R651.1
A
1672-7770(2017)01-0052-04